CANDICE SUMRALL: Open Payments
NPI 1447836168 · MCCOMB, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,647 in 182 payments from 19 companies in 2025. Trend: 2023 $2,397 · 2024 $2,459 · 2025 $3,647
Food & beverage: $3,396Education: $251
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 33 | $952 |
| GlaxoSmithKline, LLC. | 32 | $388 |
| GENZYME CORPORATION | 15 | $283 |
| Grifols USA, LLC | 10 | $270 |
| Mallinckrodt Hospital Products Inc. | 5 | $254 |
| Viatris Specialty LLC | 17 | $222 |
| Verona Pharma, Inc. | 12 | $198 |
| Amgen Inc. | 12 | $187 |
| Insmed, Inc. | 9 | $186 |
| Regeneron Healthcare Solutions, Inc. | 10 | $157 |
Products named: FASENRA, DUPIXENT, NUCALA, Prolastin-C Liquid, ACTHAR, YUPELRI, TEZSPIRE, Ohtuvayre.
Industry payments across MS — which companies pay providers there.
